Want to see IN:ROSSARI full AI Analyst Report?

Rossari Biotech Ltd (ROSSARI) Price & Analysis

2 Followers

ROSSARI Stock Chart & Stats

₹583.95

₹39.25(5.10%)

At close: Jan 08 4:00 PM EST

₹583.95

₹39.25(5.10%)

Day’s Range― - ―

52-Week Range₹372.90 - ₹690.90

Previous CloseN/A

Volume112.05K

Average Volume (3M)2.66K

Market Cap

₹28.40B

Enterprise Value₹24.03K

Total Cash (Recent Filing)₹1.15B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)18.7

Beta1.05

Next Earnings

Oct 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.1%

Share Statistics

EPS (TTM)27.22

Shares Outstanding55,391,617

10 Day Avg. Volume1,386

30 Day Avg. Volume2,661

Financial Highlights & Ratios

PEG Ratio1.51

Price to Book (P/B)1.57

Price to Sales (P/S)0.87

P/FCF Ratio-9.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)32.97

Revenue Forecast (FY)₹26.70B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent multi‑year revenue growth provides a structural tailwind: steady demand supports scale economics, improved capacity utilisation and cross‑sell opportunities. Sustained top‑line expansion underpins long‑term investment in R&D and manufacturing, enhancing resilience to sector cyclicality.

Solutions-led, Diversified End MarketsServing multiple end markets with application‑led, tailored formulations builds customer stickiness and recurring demand. Technical service and process improvements create repeat consumption and pricing power, enabling durable revenue visibility and easier wallet share expansion across industrial accounts.

Reasonably Healthy Balance Sheet & ROEA reasonably healthy balance sheet with consistent equity growth and low‑teens ROE signals acceptable capital efficiency. This position helps absorb incremental borrowing for capex or working capital, supporting measured expansion and reducing near‑term solvency risk compared with weaker peers.

Bears Say

Weak Cash Generation / Negative FCFVolatile operating cash flow and deeply negative free cash flow in 2026 point to weak cash conversion or heavy working‑capital/capex needs. Persistent negative FCF erodes financial flexibility, raises reliance on external funding, and limits ability to fund growth or shareholder returns over the medium term.

Rising LeverageSharp debt increases since 2024 have pushed leverage higher despite equity growth. Elevated indebtedness, combined with weak cash flow, raises refinancing and interest costs risk and constrains strategic flexibility, making the company more vulnerable to demand slowdowns or rate shocks over the next several quarters.

Margin PressureA meaningful gross margin decline in 2026 and only mid‑single digit net margins indicate cost or mix pressure. Sustained margin erosion would reduce the firm’s ability to invest in high‑value formulations, weaken pricing power and compress returns on new investments over the medium term.

Rossari Biotech Ltd News

Rossari Biotech Sets July 20 Investor Call on Q1 FY27 Results

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an update. Rossari Biotech Ltd has scheduled an earnings conference...

29d ago

Rossari Biotech Publishes AGM Notice and Details of E-Voting Facility

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has notified exchanges that it has...

1M ago

Rossari Biotech sets July 20 virtual AGM, proposes dividend and related-party approvals

An announcement from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Ltd has scheduled its...

2M ago

Rossari Biotech Releases Integrated Sustainability Report for FY 2025-26

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an announcement. Rossari Biotech Limited has released its Business Responsibility...

2M ago

Rossari Biotech dispatches AGM, annual report access details to non-email shareholders

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has informed stock exchanges that it...

2M ago

Rossari Biotech Faces Court Challenge to Arbitration Award in Unitop Acquisition Dispute

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech has disclosed that the sellers of...

2M ago

Rossari Biotech Publishes FY26 Audited Results Extracts in Financial Dailies

Rossari Biotech Ltd ( ($IN:ROSSARI) ) just unveiled an update. Rossari Biotech Ltd has announced that it has...

4M ago

Rossari Biotech posts record Q4 and steady FY26 growth despite margin pressure

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech reported its highest-ever quarterly performance in...

4M ago

Rossari Biotech Reschedules Subsidiaries’ Capacity Expansion in Phased Rollout

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an update. Rossari Biotech has announced that its material subsidiaries,...

4M ago

Rossari Biotech to Host Q4 FY26 Earnings Call on April 28

The latest update is out from Rossari Biotech Ltd ( ($IN:ROSSARI) ). Rossari Biotech Ltd has scheduled an...

4M ago

ROSSARI FAQ

What was Rossari Biotech Ltd’s price range in the past 12 months?

Rossari Biotech Ltd lowest stock price was ₹372.90 and its highest was ₹690.90 in the past 12 months.

What is Rossari Biotech Ltd’s market cap?

Rossari Biotech Ltd’s market cap is ₹28.40B.

When is Rossari Biotech Ltd’s upcoming earnings report date?

Rossari Biotech Ltd’s upcoming earnings report date is Oct 19, 2026 which is in 68 days.

How were Rossari Biotech Ltd’s earnings last quarter?

Rossari Biotech Ltd released its earnings results on Jul 18, 2026. The company reported ₹6.4 earnings per share for the quarter, missing the consensus estimate of ₹8.8 by -₹2.4.

Is Rossari Biotech Ltd overvalued?

According to Wall Street analysts Rossari Biotech Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rossari Biotech Ltd pay dividends?

Rossari Biotech Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.1%. See more information on Rossari Biotech Ltd dividends here

What is Rossari Biotech Ltd’s EPS estimate?

Rossari Biotech Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rossari Biotech Ltd have?

Rossari Biotech Ltd has 55,391,617 shares outstanding.

What happened to Rossari Biotech Ltd’s price movement after its last earnings report?

Rossari Biotech Ltd reported an EPS of ₹6.4 in its last earnings report, missing expectations of ₹8.8. Following the earnings report the stock price went down -1.947%.

Which hedge fund is a major shareholder of Rossari Biotech Ltd?

Currently, no hedge funds are holding shares in IN:ROSSARI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rossari Biotech Ltd

Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, paints, and coatings, materials for ceramics and tiles, solutions for pulp and paper production, components for cement, and water treatment compounds. The company also provides a broad spectrum of textile processing chemicals, supporting various fabrics like cotton, polyester, acrylic, wool, silk, and nylon, alongside functional finishes, denim treatments, and eco-friendly options. Additionally, Rossari Biotech develops pet grooming essentials such as natural shampoos, powders, deodorants, sprays, creams, and floor cleaners, marketed under brands like Lozalo, Hunger Fills, and Sniffy. Its portfolio extends to poultry nutrition products, encompassing vitamin-mineral blends, toxin binders, enzyme preparations, liquid nutraceuticals, and herbal supplements. Founded in 2003, the firm, initially named Rossari Labtech, rebranded to Rossari Biotech Limited in December of the same year and is headquartered in Mumbai, India.